AUP Aurinia Pharmaceuticals Inc.

Aurinia Will Attend 2024 RBC Capital Markets Global Healthcare Conference

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will attend the 2024 RBC Capital Markets Global Healthcare Conference in New York from May 14-15, 2024.

Aurinia management will host one-on-one meetings with investors and will participate in a fireside chat on Wednesday, May 15, from 10:00 to 10:25 AM Eastern Time. A live webcast of the session will be available on the Investor section of Aurinia’s website, which can be found

About Aurinia

Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS® (voclosporin), the first FDA-approved oral therapy dedicated to the treatment of adult patients with active lupus nephritis. The Company’s head office is in Edmonton, Alberta, its U.S. commercial office is in Rockville, Maryland. The Company focuses its development efforts globally.

EN
07/05/2024

Underlying

AUPAurinia Pharmaceuticals Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Aurinia Pharmaceuticals Inc.

 PRESS RELEASE
Free
AUP Aurinia Pharmac...

Aurinia Pharmaceuticals Reports Financial Results for the Three and Tw...

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced financial results for the three and twelve months ended December 31, 2024 and provided an update on recent corporate progress. Fourth Quarter 2024 Financial Results Total Revenue: For the three months ended December 31, 2024, total revenue was $59.9 million, up 33% from $45.1 million in the same period of 2023. – Net Product Sales: For the three months ended December 31, 2024, net product sales of LUPKYNIS, the first FDA-approved oral therapy for the treatment of adult pati...

February 27, 2025 1 EN
 PRESS RELEASE
Free
AUP Aurinia Pharmac...

Aurinia Pharmaceuticals to Release 2024 Fourth Quarter and Full Year F...

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will release 2024 fourth quarter and full year financial and operational results before markets open on February 27, 2025. Aurinia’s management team will host a conference call and webcast at 8:30 am ET that day to review these results and provide a general business update. The link to the audio webcast is available . To join the conference call, please dial 877-407-9170/ . A replay of the webcast will be available on Aurinia’s website. About Auri...

February 20, 2025 1 EN
Jonathan Moreland
  • Jonathan Moreland
Free Trial
ITW Illinois Tool W...
TTSH Tile Shop Holdi... ... (+56)

InsiderInsights Weekly Report: December 14, 2024

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

ITW ILLINOIS TOOL WORKS INC.
TTSH TILE SHOP HOLDINGS INC.
PLAY DAVE & BUSTER'S ENTERTAINMENT INC.
MYE MYERS INDUSTRIES INC.
MTDR MATADOR RESOURCES COMPANY
LTRX LANTRONIX INC.
HRZN HORIZON TECHNOLOGY FINANCE CORP.
FCN FTI CONSULTING INC.
CVGI COMMERCIAL VEHICLE GROUP INC.
BAH BOOZ ALLEN HAMILTON HOLDING CORPORATION CLASS A
MEDP MEDPACE HOLDINGS INC.
AUP AURINIA PHARMACEUTICALS INC.
CULP CULP INC.
PETS PETMED EXPRESS INC.
SCVL SHOE CARNIVAL INC.
TREE LENDINGTREE INC.
PMD PSYCHEMEDICS CORP.
DMLP DORCHESTER MINERALS L.P.
LILA LIBERTY LATIN AMERICA A
HHS HARTE-HANKS INC.
ETST EARTH SCIENCE TECH
TCPC BLACKROCK TCP CAPITAL CORP.
DBI DESIGNER BRANDS INC. CLASS A
ORGO ORGANOGENESIS HOLDINGS (A)
ETNB 89BIO
PCB PACIFIC CITY FINANCIAL CORP
RZLT REZOLUTE
RVMD INC.
SSSS REVOLUTION MEDICINES
FTHM SUTTER ROCK CAPITAL CORP.
GNSS FATHOM HOLDINGS
CTGO GENASYS INC
AGL CONTANGO ORE INC.
NOTV AGILON HEALTH
AUID INC.
TRIN INOTIV
TCBX INC.
IBRX IPSIDY INC.
BIGZ TRINITY CAPITAL INC
MODD THIRD COAST BANCSHARES INC
GRNT IMMUNITYBIO INC
UAMY BLACKROCK INNOVATION AND GROWTH TST
TKO MODULAR MEDICAL INC
SRBK GRANITE RIDGE RESOURCES INC
NCDL U S ANTIMONY CORP
SPRU TKO GROUP HOLDINGS
AVDL INC.
CATX SR BANCORP INC
MRAI NUVEEN CHURCHILL DIRECT LENDING CORP
GWAV SPRUCE POWER HOLDING CORP
AVADEL PHARMACEUTICALS PUBLIC LIMITED COMPANY
PERSPECTIVE THERAPEUTICS
INC.
MARPAI
INC.
GREENWAVE TECHNOLOGY SOLUTIONS INC
12/15/24 December 15, 2024 1 EN
Jonathan Moreland
  • Jonathan Moreland
Free Trial
TTSH Tile Shop Holdi...
NMFC New Mountain Fi... ... (+19)

InsiderInsights.com Daily Ratings Report: December 9, 2024

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

TTSH TILE SHOP HOLDINGS INC.
NMFC NEW MOUNTAIN FINANCE CORPORATION
AUP AURINIA PHARMACEUTICALS INC.
SCVL SHOE CARNIVAL INC.
TREE LENDINGTREE INC.
MHI PIONEER MUNICIPAL HIGH INCOME TRUST
QRTEA QURATE RETAIL INC. CLASS A
ORGO ORGANOGENESIS HOLDINGS (A)
ATEX ANTERIX
ETNB 89BIO
ENX EATON VANCE NEW YORK MUNICIPAL BOND FUND
ONEW ONEWATER MARINE
RVMD REVOLUTION MEDICINES
BIGZ BLACKROCK INNOVATION AND GROWTH TST
GRNT GRANITE RIDGE RESOURCES INC
SRBK SR BANCORP INC
MRAI MARPAI
EVM INC.
EATON VANCE INSD CALIF MUN BD FD
12/10/24 December 10, 2024 1 EN
 PRESS RELEASE
Free
AUP Aurinia Pharmac...

Aurinia Commends 2024 Updated ACR Guidelines for Screening, Treatment,...

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) commends the American College of Rheumatology (ACR) for their 2024 evidence-based guidelines for the screening, treatment, and management of lupus nephritis (LN), which prioritize the urgent need to use efficacious treatments to avoid nephron loss and preserve kidney function. The guidelines call for a triple immunosuppression treatment regimen for LN, with first line use of advanced therapies like LUPKYNIS for three to five years. Importantly, the guidelines suggest tha...

November 18, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch